The Research Institute of Molecular Pathology (IMP) is a leading basic research institute. Its 15 research groups with scientists from 40 countries address fundamental questions in molecular biology. Funded primarily by Boehringer Ingelheim and with unconstrained academic freedom, the IMP is the ideal environment for curiosity-driven biomedical research. As part of the Vienna Biocenter (VBC), the IMP is embedded in one of Europe’s biggest life science hubs with 1400 researchers.

Since the IMP’s establishment in 1985, scientists at the institute are addressing important problems in research areas including molecular and cellular biology; structural biology and biochemistry; gene expression and chromosome biology; stem cell biology and development; immunology and cancer; and neuroscience.

In pursuit of their research goals, scientists at the IMP employ the latest methods and equipment in molecular genetics, imaging, biochemistry and structural biology on an array of model systems.
This is achieved with the help of state-of-the-art core facilities that are available to all research groups free of charge. Research at the IMP is supported by an annual budget of approximately 28 million Euros.